Iterum Therapeutics Investor Relations Material
Latest events
Status Update
Iterum Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Iterum Therapeutics plc
Access all reports
Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing novel anti-infective therapies. The company is working on next-generation oral and intravenous antibiotics designed to combat infections caused by multi-drug resistant pathogens, which are a growing global health concern. Iterum's lead product candidate, sulopenem, is a novel penem antibiotic that has shown potent activity against a broad spectrum of bacteria, including strains that are resistant to other antibiotics. Iterum Therapeutics is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ITRM
Country
🇺🇸 United States